Cape Verde vs Ghana: Average cost of multi drug-resistant tuberculosis treatment
Cape Verde
500 constant 2022 US$
in 2024
Ghana
500 constant 2022 US$
in 2024
Cape Verde rank
78th
Ghana rank
78th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cape Verde
- Ghana
How they compare
Cape Verde currently reports 500 constant 2022 US$ against 500 constant 2022 US$ in Ghana, a difference of 0 constant 2022 US$.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Cape Verde ahead.
Cape Verde ranks 78th and Ghana ranks 78th of 92 countries.
Ghana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cape Verde | Ghana | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,500 constant 2022 US$ | 1,860 constant 2022 US$ | 359.67 constant 2022 US$ | Ghana |
| 2020s | 1,100 constant 2022 US$ | 1,116 constant 2022 US$ | 15.8 constant 2022 US$ | Ghana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cape Verde or Ghana?
- Cape Verde, at 500 constant 2022 US$ against 500 constant 2022 US$ in Ghana as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cape Verde and Ghana?
- 0 constant 2022 US$, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and Ghana?
- 8 years are reported by both, from 2017 to 2024.
- How do Cape Verde and Ghana rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cape Verde ranks 78th and Ghana ranks 78th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.